Type 1 vs. Type 2 Diabetes: Understanding the Key Differences
Type 1 vs. Type 2 Diabetes: Distinct Pathophysiology, Presentation & Management
Both cause hyperglycemia but differ fundamentally in etiology, onset, treatment, and risk profile.
Pathophysiology
| Feature | Type 1 Diabetes (T1D) | Type 2 Diabetes (T2D) |
|---|---|---|
| Primary defect | Autoimmune β-cell destruction → absolute insulin deficiency | Insulin resistance + relative insulin deficiency (β-cell dysfunction) |
| Genetics | HLA-DR3/DR4-DQ8 (50% risk); polygenic; <10% familial | Strong polygenic (TCF7L2, etc.); >50% have affected first-degree relative |
| Environmental triggers | Viral (enterovirus), early diet, vitamin D, hygiene hypothesis | Obesity, inactivity, aging, intrauterine environment, sleep, stress |
| Onset age | Peak 10-14 yr; any age (LADA = adult-onset T1D) | Typically >40 yr; rising in youth with obesity |
| Body habitus | Often lean/weight loss at onset | Often overweight/obese (but not always) |
| Ketoacidosis risk | High at diagnosis (30-40%); recurrent if insulin omitted | Rare (ketosis-prone T2D subset) |
| C-peptide | Low/undetectable | Normal/high early; declines over years |
| Autoantibodies | GAD65, IA-2, ZnT8, IAA, ICA (+ in 85-90% at dx) | Negative |
Clinical Presentation
- T1D: Polyuria, polydipsia, polyphagia, weight loss, fatigue, blurred vision — acute/subacute (weeks).
- T2D: Often asymptomatic; screening detection. Symptoms: polyuria, polydipsia, blurred vision, recurrent infections, acanthosis nigricans, slow healing — insidious (years).
Treatment Paradigms
| Aspect | T1D | T2D |
|---|---|---|
| Insulin | Mandatory (basal-bolus MDI or pump) | Progressive need (30-50% at 10 yr); not initial |
| Non-insulin agents | Adjunct only (metformin, SGLT2i, GLP-1 RA for insulin resistance/comorbidities) | First-line: Metformin + lifestyle; escalate per ADA/EASD algorithm (GLP-1 RA, SGLT2i for CVD/CKD benefit) |
| Glucose monitoring | CGM standard of care; fingerstick backup | CGM if on insulin/high risk; SMBG if oral agents only |
| Education focus | Carb counting, insulin dosing, sick-day rules, DKA prevention, tech | Lifestyle modification, medication adherence, monitoring, complication screening |
Complications (Both)
- Microvascular: Retinopathy, nephropathy, neuropathy.
- Macrovascular: ASCVD (MI, stroke, PAD) — 2-4x risk.
- Acute: DKA (T1D > T2D), HHS (T2D > T1D), hypoglycemia (insulin/sulfonylurea).
Key Takeaway
T1D = insulin deficiency (autoimmune) → insulin replacement essential.
T2D = insulin resistance + β-cell failure → lifestyle + progressive pharmacotherapy.
Correct classification guides therapy. Misdiagnosis (LADA as T2D) delays insulin, risks DKA.
Diabetes - Related Articles
- Brittle Diabetes: Symptoms, Causes & Management | [Your Brand Name]
- Understanding Insulin Resistance: Why Blood Sugar Remains High
- Diabetes in Georgia: Prevalence, Statistics & Trends (2022)
- Diabetes-Related Finger Gangrene: Causes, Symptoms & Prevention
- Ascensia Breeze Meter: Simplify Your Diabetes Management
- Diabetic Ketoacidosis (DKA): Causes, Symptoms & Treatment
- Understanding Ketones in Diabetes: Causes & Implications
